| Vibrant Vitality Medical Wellness Center Pc | |
|
13175 Haskell Pl Carmel IN 46074-8332 | |
| (317) 850-6496 | |
| Not Available |
| Full Name | Vibrant Vitality Medical Wellness Center Pc |
|---|---|
| Speciality | General Practice |
| Location | 13175 Haskell Pl, Carmel, Indiana |
| Authorized Official Name and Position | Ted T Lai (MEDICAL DIRECTOR) |
| Authorized Official Contact | 3178506496 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Vibrant Vitality Medical Wellness Center Pc 13175 Haskell Pl Carmel IN 46074-8332 Ph: (317) 850-6496 | Vibrant Vitality Medical Wellness Center Pc 13175 Haskell Pl Carmel IN 46074-8332 Ph: (317) 850-6496 |
| NPI Number | 1265891279 |
|---|---|
| Provider Enumeration Date | 02/18/2016 |
| Last Update Date | 02/18/2016 |
| Medicare PECOS PAC ID | 6002106093 |
|---|---|
| Medicare Enrollment ID | O20160603000071 |
News Archive
Mindray Medical International Limited, a leading developer, manufacturer and marketer of medical devices worldwide, announced today the completion of its acquisition of Wuhan Dragonbio Surgical Implant's orthopedics business pursuant to the terms of the definitive agreement entered into on June 6, 2012.
Dendreon Corporation today announced that the U.S. Food and Drug Administration (FDA) provided written acknowledgement that the Company's amended Biologics License Application (BLA) for PROVENGE® (sipuleucel-T) is a complete response. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) date of May 1, 2010, by which time it will respond to Dendreon's amended BLA. Dendreon is seeking licensure for PROVENGE for men with metastatic castrate-resistant prostate cancer (CRPC).
Researchers have just established a structural basis for two spike glycoprotein epitopes of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that are restricted to human leukocyte antigen (HLA) A2 molecules. More specifically, they are involved in the presentation of antigenic peptides to specific T lymphocytes and recognized by public and private T cell receptors. The research is currently available on the bioRxiv* preprint server.
Forest Laboratories, Inc. and Mylan Inc. announced that Mylan has received an approvable letter from the U.S. Food and Drug Administration (FDA) in response to its New Drug Application (NDA) for nebivolol (proposed brand name Bystolic), a novel beta blocker under review for the treatment of hypertension.
In many pharmaceutical company and university laboratories, scientists are looking closely at kinase complexes because the enzymes play key roles in essential cell functions. By taking unusual steps to examine a kinase complex, researchers at Brown University and the National Institutes of Health have found a sought-after prize: an unprecedentedly detailed description of its structure complete with a rare location on its structure that could be a target for new therapeutic drugs.
› Verified 8 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1265891279 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208D00000X | General Practice | 50005071A (Indiana) | Primary |
| Provider Name | Ted T Lai |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1982691671 PECOS PAC ID: 4183684855 Enrollment ID: I20041016000228 |
News Archive
Mindray Medical International Limited, a leading developer, manufacturer and marketer of medical devices worldwide, announced today the completion of its acquisition of Wuhan Dragonbio Surgical Implant's orthopedics business pursuant to the terms of the definitive agreement entered into on June 6, 2012.
Dendreon Corporation today announced that the U.S. Food and Drug Administration (FDA) provided written acknowledgement that the Company's amended Biologics License Application (BLA) for PROVENGE® (sipuleucel-T) is a complete response. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) date of May 1, 2010, by which time it will respond to Dendreon's amended BLA. Dendreon is seeking licensure for PROVENGE for men with metastatic castrate-resistant prostate cancer (CRPC).
Researchers have just established a structural basis for two spike glycoprotein epitopes of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that are restricted to human leukocyte antigen (HLA) A2 molecules. More specifically, they are involved in the presentation of antigenic peptides to specific T lymphocytes and recognized by public and private T cell receptors. The research is currently available on the bioRxiv* preprint server.
Forest Laboratories, Inc. and Mylan Inc. announced that Mylan has received an approvable letter from the U.S. Food and Drug Administration (FDA) in response to its New Drug Application (NDA) for nebivolol (proposed brand name Bystolic), a novel beta blocker under review for the treatment of hypertension.
In many pharmaceutical company and university laboratories, scientists are looking closely at kinase complexes because the enzymes play key roles in essential cell functions. By taking unusual steps to examine a kinase complex, researchers at Brown University and the National Institutes of Health have found a sought-after prize: an unprecedentedly detailed description of its structure complete with a rare location on its structure that could be a target for new therapeutic drugs.
› Verified 8 days ago
| Provider Name | Annamarie Salyer |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1386041853 PECOS PAC ID: 2860710183 Enrollment ID: I20150417000797 |
News Archive
Mindray Medical International Limited, a leading developer, manufacturer and marketer of medical devices worldwide, announced today the completion of its acquisition of Wuhan Dragonbio Surgical Implant's orthopedics business pursuant to the terms of the definitive agreement entered into on June 6, 2012.
Dendreon Corporation today announced that the U.S. Food and Drug Administration (FDA) provided written acknowledgement that the Company's amended Biologics License Application (BLA) for PROVENGE® (sipuleucel-T) is a complete response. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) date of May 1, 2010, by which time it will respond to Dendreon's amended BLA. Dendreon is seeking licensure for PROVENGE for men with metastatic castrate-resistant prostate cancer (CRPC).
Researchers have just established a structural basis for two spike glycoprotein epitopes of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that are restricted to human leukocyte antigen (HLA) A2 molecules. More specifically, they are involved in the presentation of antigenic peptides to specific T lymphocytes and recognized by public and private T cell receptors. The research is currently available on the bioRxiv* preprint server.
Forest Laboratories, Inc. and Mylan Inc. announced that Mylan has received an approvable letter from the U.S. Food and Drug Administration (FDA) in response to its New Drug Application (NDA) for nebivolol (proposed brand name Bystolic), a novel beta blocker under review for the treatment of hypertension.
In many pharmaceutical company and university laboratories, scientists are looking closely at kinase complexes because the enzymes play key roles in essential cell functions. By taking unusual steps to examine a kinase complex, researchers at Brown University and the National Institutes of Health have found a sought-after prize: an unprecedentedly detailed description of its structure complete with a rare location on its structure that could be a target for new therapeutic drugs.
› Verified 8 days ago
| Provider Name | Nicholle M Hise |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1023472735 PECOS PAC ID: 5193024818 Enrollment ID: I20160502002230 |
News Archive
Mindray Medical International Limited, a leading developer, manufacturer and marketer of medical devices worldwide, announced today the completion of its acquisition of Wuhan Dragonbio Surgical Implant's orthopedics business pursuant to the terms of the definitive agreement entered into on June 6, 2012.
Dendreon Corporation today announced that the U.S. Food and Drug Administration (FDA) provided written acknowledgement that the Company's amended Biologics License Application (BLA) for PROVENGE® (sipuleucel-T) is a complete response. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) date of May 1, 2010, by which time it will respond to Dendreon's amended BLA. Dendreon is seeking licensure for PROVENGE for men with metastatic castrate-resistant prostate cancer (CRPC).
Researchers have just established a structural basis for two spike glycoprotein epitopes of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that are restricted to human leukocyte antigen (HLA) A2 molecules. More specifically, they are involved in the presentation of antigenic peptides to specific T lymphocytes and recognized by public and private T cell receptors. The research is currently available on the bioRxiv* preprint server.
Forest Laboratories, Inc. and Mylan Inc. announced that Mylan has received an approvable letter from the U.S. Food and Drug Administration (FDA) in response to its New Drug Application (NDA) for nebivolol (proposed brand name Bystolic), a novel beta blocker under review for the treatment of hypertension.
In many pharmaceutical company and university laboratories, scientists are looking closely at kinase complexes because the enzymes play key roles in essential cell functions. By taking unusual steps to examine a kinase complex, researchers at Brown University and the National Institutes of Health have found a sought-after prize: an unprecedentedly detailed description of its structure complete with a rare location on its structure that could be a target for new therapeutic drugs.
› Verified 8 days ago
| Provider Name | Melissa Leann Humburg |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1841745577 PECOS PAC ID: 3274813522 Enrollment ID: I20161205000113 |
News Archive
Mindray Medical International Limited, a leading developer, manufacturer and marketer of medical devices worldwide, announced today the completion of its acquisition of Wuhan Dragonbio Surgical Implant's orthopedics business pursuant to the terms of the definitive agreement entered into on June 6, 2012.
Dendreon Corporation today announced that the U.S. Food and Drug Administration (FDA) provided written acknowledgement that the Company's amended Biologics License Application (BLA) for PROVENGE® (sipuleucel-T) is a complete response. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) date of May 1, 2010, by which time it will respond to Dendreon's amended BLA. Dendreon is seeking licensure for PROVENGE for men with metastatic castrate-resistant prostate cancer (CRPC).
Researchers have just established a structural basis for two spike glycoprotein epitopes of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that are restricted to human leukocyte antigen (HLA) A2 molecules. More specifically, they are involved in the presentation of antigenic peptides to specific T lymphocytes and recognized by public and private T cell receptors. The research is currently available on the bioRxiv* preprint server.
Forest Laboratories, Inc. and Mylan Inc. announced that Mylan has received an approvable letter from the U.S. Food and Drug Administration (FDA) in response to its New Drug Application (NDA) for nebivolol (proposed brand name Bystolic), a novel beta blocker under review for the treatment of hypertension.
In many pharmaceutical company and university laboratories, scientists are looking closely at kinase complexes because the enzymes play key roles in essential cell functions. By taking unusual steps to examine a kinase complex, researchers at Brown University and the National Institutes of Health have found a sought-after prize: an unprecedentedly detailed description of its structure complete with a rare location on its structure that could be a target for new therapeutic drugs.
› Verified 8 days ago
| Provider Name | Sarah M Jayroe |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1083169932 PECOS PAC ID: 6507146503 Enrollment ID: I20161209000071 |
News Archive
Mindray Medical International Limited, a leading developer, manufacturer and marketer of medical devices worldwide, announced today the completion of its acquisition of Wuhan Dragonbio Surgical Implant's orthopedics business pursuant to the terms of the definitive agreement entered into on June 6, 2012.
Dendreon Corporation today announced that the U.S. Food and Drug Administration (FDA) provided written acknowledgement that the Company's amended Biologics License Application (BLA) for PROVENGE® (sipuleucel-T) is a complete response. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) date of May 1, 2010, by which time it will respond to Dendreon's amended BLA. Dendreon is seeking licensure for PROVENGE for men with metastatic castrate-resistant prostate cancer (CRPC).
Researchers have just established a structural basis for two spike glycoprotein epitopes of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that are restricted to human leukocyte antigen (HLA) A2 molecules. More specifically, they are involved in the presentation of antigenic peptides to specific T lymphocytes and recognized by public and private T cell receptors. The research is currently available on the bioRxiv* preprint server.
Forest Laboratories, Inc. and Mylan Inc. announced that Mylan has received an approvable letter from the U.S. Food and Drug Administration (FDA) in response to its New Drug Application (NDA) for nebivolol (proposed brand name Bystolic), a novel beta blocker under review for the treatment of hypertension.
In many pharmaceutical company and university laboratories, scientists are looking closely at kinase complexes because the enzymes play key roles in essential cell functions. By taking unusual steps to examine a kinase complex, researchers at Brown University and the National Institutes of Health have found a sought-after prize: an unprecedentedly detailed description of its structure complete with a rare location on its structure that could be a target for new therapeutic drugs.
› Verified 8 days ago
| Provider Name | Scott F Wood |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1912449273 PECOS PAC ID: 1759661630 Enrollment ID: I20161212000691 |
News Archive
Mindray Medical International Limited, a leading developer, manufacturer and marketer of medical devices worldwide, announced today the completion of its acquisition of Wuhan Dragonbio Surgical Implant's orthopedics business pursuant to the terms of the definitive agreement entered into on June 6, 2012.
Dendreon Corporation today announced that the U.S. Food and Drug Administration (FDA) provided written acknowledgement that the Company's amended Biologics License Application (BLA) for PROVENGE® (sipuleucel-T) is a complete response. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) date of May 1, 2010, by which time it will respond to Dendreon's amended BLA. Dendreon is seeking licensure for PROVENGE for men with metastatic castrate-resistant prostate cancer (CRPC).
Researchers have just established a structural basis for two spike glycoprotein epitopes of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that are restricted to human leukocyte antigen (HLA) A2 molecules. More specifically, they are involved in the presentation of antigenic peptides to specific T lymphocytes and recognized by public and private T cell receptors. The research is currently available on the bioRxiv* preprint server.
Forest Laboratories, Inc. and Mylan Inc. announced that Mylan has received an approvable letter from the U.S. Food and Drug Administration (FDA) in response to its New Drug Application (NDA) for nebivolol (proposed brand name Bystolic), a novel beta blocker under review for the treatment of hypertension.
In many pharmaceutical company and university laboratories, scientists are looking closely at kinase complexes because the enzymes play key roles in essential cell functions. By taking unusual steps to examine a kinase complex, researchers at Brown University and the National Institutes of Health have found a sought-after prize: an unprecedentedly detailed description of its structure complete with a rare location on its structure that could be a target for new therapeutic drugs.
› Verified 8 days ago
| Provider Name | Sei Young V Kwak |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1689126674 PECOS PAC ID: 4587949946 Enrollment ID: I20170327001574 |
News Archive
Mindray Medical International Limited, a leading developer, manufacturer and marketer of medical devices worldwide, announced today the completion of its acquisition of Wuhan Dragonbio Surgical Implant's orthopedics business pursuant to the terms of the definitive agreement entered into on June 6, 2012.
Dendreon Corporation today announced that the U.S. Food and Drug Administration (FDA) provided written acknowledgement that the Company's amended Biologics License Application (BLA) for PROVENGE® (sipuleucel-T) is a complete response. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) date of May 1, 2010, by which time it will respond to Dendreon's amended BLA. Dendreon is seeking licensure for PROVENGE for men with metastatic castrate-resistant prostate cancer (CRPC).
Researchers have just established a structural basis for two spike glycoprotein epitopes of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that are restricted to human leukocyte antigen (HLA) A2 molecules. More specifically, they are involved in the presentation of antigenic peptides to specific T lymphocytes and recognized by public and private T cell receptors. The research is currently available on the bioRxiv* preprint server.
Forest Laboratories, Inc. and Mylan Inc. announced that Mylan has received an approvable letter from the U.S. Food and Drug Administration (FDA) in response to its New Drug Application (NDA) for nebivolol (proposed brand name Bystolic), a novel beta blocker under review for the treatment of hypertension.
In many pharmaceutical company and university laboratories, scientists are looking closely at kinase complexes because the enzymes play key roles in essential cell functions. By taking unusual steps to examine a kinase complex, researchers at Brown University and the National Institutes of Health have found a sought-after prize: an unprecedentedly detailed description of its structure complete with a rare location on its structure that could be a target for new therapeutic drugs.
› Verified 8 days ago
| Provider Name | Rebecca K Barger |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1275072811 PECOS PAC ID: 6406133958 Enrollment ID: I20170510001270 |
News Archive
Mindray Medical International Limited, a leading developer, manufacturer and marketer of medical devices worldwide, announced today the completion of its acquisition of Wuhan Dragonbio Surgical Implant's orthopedics business pursuant to the terms of the definitive agreement entered into on June 6, 2012.
Dendreon Corporation today announced that the U.S. Food and Drug Administration (FDA) provided written acknowledgement that the Company's amended Biologics License Application (BLA) for PROVENGE® (sipuleucel-T) is a complete response. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) date of May 1, 2010, by which time it will respond to Dendreon's amended BLA. Dendreon is seeking licensure for PROVENGE for men with metastatic castrate-resistant prostate cancer (CRPC).
Researchers have just established a structural basis for two spike glycoprotein epitopes of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that are restricted to human leukocyte antigen (HLA) A2 molecules. More specifically, they are involved in the presentation of antigenic peptides to specific T lymphocytes and recognized by public and private T cell receptors. The research is currently available on the bioRxiv* preprint server.
Forest Laboratories, Inc. and Mylan Inc. announced that Mylan has received an approvable letter from the U.S. Food and Drug Administration (FDA) in response to its New Drug Application (NDA) for nebivolol (proposed brand name Bystolic), a novel beta blocker under review for the treatment of hypertension.
In many pharmaceutical company and university laboratories, scientists are looking closely at kinase complexes because the enzymes play key roles in essential cell functions. By taking unusual steps to examine a kinase complex, researchers at Brown University and the National Institutes of Health have found a sought-after prize: an unprecedentedly detailed description of its structure complete with a rare location on its structure that could be a target for new therapeutic drugs.
› Verified 8 days ago
| Provider Name | Erin R Brophy |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1851837702 PECOS PAC ID: 8729355144 Enrollment ID: I20170606000934 |
News Archive
Mindray Medical International Limited, a leading developer, manufacturer and marketer of medical devices worldwide, announced today the completion of its acquisition of Wuhan Dragonbio Surgical Implant's orthopedics business pursuant to the terms of the definitive agreement entered into on June 6, 2012.
Dendreon Corporation today announced that the U.S. Food and Drug Administration (FDA) provided written acknowledgement that the Company's amended Biologics License Application (BLA) for PROVENGE® (sipuleucel-T) is a complete response. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) date of May 1, 2010, by which time it will respond to Dendreon's amended BLA. Dendreon is seeking licensure for PROVENGE for men with metastatic castrate-resistant prostate cancer (CRPC).
Researchers have just established a structural basis for two spike glycoprotein epitopes of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that are restricted to human leukocyte antigen (HLA) A2 molecules. More specifically, they are involved in the presentation of antigenic peptides to specific T lymphocytes and recognized by public and private T cell receptors. The research is currently available on the bioRxiv* preprint server.
Forest Laboratories, Inc. and Mylan Inc. announced that Mylan has received an approvable letter from the U.S. Food and Drug Administration (FDA) in response to its New Drug Application (NDA) for nebivolol (proposed brand name Bystolic), a novel beta blocker under review for the treatment of hypertension.
In many pharmaceutical company and university laboratories, scientists are looking closely at kinase complexes because the enzymes play key roles in essential cell functions. By taking unusual steps to examine a kinase complex, researchers at Brown University and the National Institutes of Health have found a sought-after prize: an unprecedentedly detailed description of its structure complete with a rare location on its structure that could be a target for new therapeutic drugs.
› Verified 8 days ago
| Provider Name | Sarah B Lawson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1114452604 PECOS PAC ID: 3678843174 Enrollment ID: I20170717000844 |
News Archive
Mindray Medical International Limited, a leading developer, manufacturer and marketer of medical devices worldwide, announced today the completion of its acquisition of Wuhan Dragonbio Surgical Implant's orthopedics business pursuant to the terms of the definitive agreement entered into on June 6, 2012.
Dendreon Corporation today announced that the U.S. Food and Drug Administration (FDA) provided written acknowledgement that the Company's amended Biologics License Application (BLA) for PROVENGE® (sipuleucel-T) is a complete response. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) date of May 1, 2010, by which time it will respond to Dendreon's amended BLA. Dendreon is seeking licensure for PROVENGE for men with metastatic castrate-resistant prostate cancer (CRPC).
Researchers have just established a structural basis for two spike glycoprotein epitopes of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that are restricted to human leukocyte antigen (HLA) A2 molecules. More specifically, they are involved in the presentation of antigenic peptides to specific T lymphocytes and recognized by public and private T cell receptors. The research is currently available on the bioRxiv* preprint server.
Forest Laboratories, Inc. and Mylan Inc. announced that Mylan has received an approvable letter from the U.S. Food and Drug Administration (FDA) in response to its New Drug Application (NDA) for nebivolol (proposed brand name Bystolic), a novel beta blocker under review for the treatment of hypertension.
In many pharmaceutical company and university laboratories, scientists are looking closely at kinase complexes because the enzymes play key roles in essential cell functions. By taking unusual steps to examine a kinase complex, researchers at Brown University and the National Institutes of Health have found a sought-after prize: an unprecedentedly detailed description of its structure complete with a rare location on its structure that could be a target for new therapeutic drugs.
› Verified 8 days ago
| Provider Name | Ricci Contessa Belisario |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1720437056 PECOS PAC ID: 4385919497 Enrollment ID: I20171120002723 |
News Archive
Mindray Medical International Limited, a leading developer, manufacturer and marketer of medical devices worldwide, announced today the completion of its acquisition of Wuhan Dragonbio Surgical Implant's orthopedics business pursuant to the terms of the definitive agreement entered into on June 6, 2012.
Dendreon Corporation today announced that the U.S. Food and Drug Administration (FDA) provided written acknowledgement that the Company's amended Biologics License Application (BLA) for PROVENGE® (sipuleucel-T) is a complete response. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) date of May 1, 2010, by which time it will respond to Dendreon's amended BLA. Dendreon is seeking licensure for PROVENGE for men with metastatic castrate-resistant prostate cancer (CRPC).
Researchers have just established a structural basis for two spike glycoprotein epitopes of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that are restricted to human leukocyte antigen (HLA) A2 molecules. More specifically, they are involved in the presentation of antigenic peptides to specific T lymphocytes and recognized by public and private T cell receptors. The research is currently available on the bioRxiv* preprint server.
Forest Laboratories, Inc. and Mylan Inc. announced that Mylan has received an approvable letter from the U.S. Food and Drug Administration (FDA) in response to its New Drug Application (NDA) for nebivolol (proposed brand name Bystolic), a novel beta blocker under review for the treatment of hypertension.
In many pharmaceutical company and university laboratories, scientists are looking closely at kinase complexes because the enzymes play key roles in essential cell functions. By taking unusual steps to examine a kinase complex, researchers at Brown University and the National Institutes of Health have found a sought-after prize: an unprecedentedly detailed description of its structure complete with a rare location on its structure that could be a target for new therapeutic drugs.
› Verified 8 days ago
| Provider Name | Sarah Anne Keehn |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1891277802 PECOS PAC ID: 4587900196 Enrollment ID: I20190117002661 |
News Archive
Mindray Medical International Limited, a leading developer, manufacturer and marketer of medical devices worldwide, announced today the completion of its acquisition of Wuhan Dragonbio Surgical Implant's orthopedics business pursuant to the terms of the definitive agreement entered into on June 6, 2012.
Dendreon Corporation today announced that the U.S. Food and Drug Administration (FDA) provided written acknowledgement that the Company's amended Biologics License Application (BLA) for PROVENGE® (sipuleucel-T) is a complete response. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) date of May 1, 2010, by which time it will respond to Dendreon's amended BLA. Dendreon is seeking licensure for PROVENGE for men with metastatic castrate-resistant prostate cancer (CRPC).
Researchers have just established a structural basis for two spike glycoprotein epitopes of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that are restricted to human leukocyte antigen (HLA) A2 molecules. More specifically, they are involved in the presentation of antigenic peptides to specific T lymphocytes and recognized by public and private T cell receptors. The research is currently available on the bioRxiv* preprint server.
Forest Laboratories, Inc. and Mylan Inc. announced that Mylan has received an approvable letter from the U.S. Food and Drug Administration (FDA) in response to its New Drug Application (NDA) for nebivolol (proposed brand name Bystolic), a novel beta blocker under review for the treatment of hypertension.
In many pharmaceutical company and university laboratories, scientists are looking closely at kinase complexes because the enzymes play key roles in essential cell functions. By taking unusual steps to examine a kinase complex, researchers at Brown University and the National Institutes of Health have found a sought-after prize: an unprecedentedly detailed description of its structure complete with a rare location on its structure that could be a target for new therapeutic drugs.
› Verified 8 days ago
| Provider Name | Stephanie N Preston |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1447882840 PECOS PAC ID: 1052741295 Enrollment ID: I20200430001839 |
News Archive
Mindray Medical International Limited, a leading developer, manufacturer and marketer of medical devices worldwide, announced today the completion of its acquisition of Wuhan Dragonbio Surgical Implant's orthopedics business pursuant to the terms of the definitive agreement entered into on June 6, 2012.
Dendreon Corporation today announced that the U.S. Food and Drug Administration (FDA) provided written acknowledgement that the Company's amended Biologics License Application (BLA) for PROVENGE® (sipuleucel-T) is a complete response. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) date of May 1, 2010, by which time it will respond to Dendreon's amended BLA. Dendreon is seeking licensure for PROVENGE for men with metastatic castrate-resistant prostate cancer (CRPC).
Researchers have just established a structural basis for two spike glycoprotein epitopes of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that are restricted to human leukocyte antigen (HLA) A2 molecules. More specifically, they are involved in the presentation of antigenic peptides to specific T lymphocytes and recognized by public and private T cell receptors. The research is currently available on the bioRxiv* preprint server.
Forest Laboratories, Inc. and Mylan Inc. announced that Mylan has received an approvable letter from the U.S. Food and Drug Administration (FDA) in response to its New Drug Application (NDA) for nebivolol (proposed brand name Bystolic), a novel beta blocker under review for the treatment of hypertension.
In many pharmaceutical company and university laboratories, scientists are looking closely at kinase complexes because the enzymes play key roles in essential cell functions. By taking unusual steps to examine a kinase complex, researchers at Brown University and the National Institutes of Health have found a sought-after prize: an unprecedentedly detailed description of its structure complete with a rare location on its structure that could be a target for new therapeutic drugs.
› Verified 8 days ago
| Provider Name | Amber Lynn Dever |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1700412855 PECOS PAC ID: 4284048083 Enrollment ID: I20210205000333 |
News Archive
Mindray Medical International Limited, a leading developer, manufacturer and marketer of medical devices worldwide, announced today the completion of its acquisition of Wuhan Dragonbio Surgical Implant's orthopedics business pursuant to the terms of the definitive agreement entered into on June 6, 2012.
Dendreon Corporation today announced that the U.S. Food and Drug Administration (FDA) provided written acknowledgement that the Company's amended Biologics License Application (BLA) for PROVENGE® (sipuleucel-T) is a complete response. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) date of May 1, 2010, by which time it will respond to Dendreon's amended BLA. Dendreon is seeking licensure for PROVENGE for men with metastatic castrate-resistant prostate cancer (CRPC).
Researchers have just established a structural basis for two spike glycoprotein epitopes of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that are restricted to human leukocyte antigen (HLA) A2 molecules. More specifically, they are involved in the presentation of antigenic peptides to specific T lymphocytes and recognized by public and private T cell receptors. The research is currently available on the bioRxiv* preprint server.
Forest Laboratories, Inc. and Mylan Inc. announced that Mylan has received an approvable letter from the U.S. Food and Drug Administration (FDA) in response to its New Drug Application (NDA) for nebivolol (proposed brand name Bystolic), a novel beta blocker under review for the treatment of hypertension.
In many pharmaceutical company and university laboratories, scientists are looking closely at kinase complexes because the enzymes play key roles in essential cell functions. By taking unusual steps to examine a kinase complex, researchers at Brown University and the National Institutes of Health have found a sought-after prize: an unprecedentedly detailed description of its structure complete with a rare location on its structure that could be a target for new therapeutic drugs.
› Verified 8 days ago
| Provider Name | Carmin M Stevenson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1306593124 PECOS PAC ID: 6305226085 Enrollment ID: I20220712002521 |
News Archive
Mindray Medical International Limited, a leading developer, manufacturer and marketer of medical devices worldwide, announced today the completion of its acquisition of Wuhan Dragonbio Surgical Implant's orthopedics business pursuant to the terms of the definitive agreement entered into on June 6, 2012.
Dendreon Corporation today announced that the U.S. Food and Drug Administration (FDA) provided written acknowledgement that the Company's amended Biologics License Application (BLA) for PROVENGE® (sipuleucel-T) is a complete response. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) date of May 1, 2010, by which time it will respond to Dendreon's amended BLA. Dendreon is seeking licensure for PROVENGE for men with metastatic castrate-resistant prostate cancer (CRPC).
Researchers have just established a structural basis for two spike glycoprotein epitopes of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that are restricted to human leukocyte antigen (HLA) A2 molecules. More specifically, they are involved in the presentation of antigenic peptides to specific T lymphocytes and recognized by public and private T cell receptors. The research is currently available on the bioRxiv* preprint server.
Forest Laboratories, Inc. and Mylan Inc. announced that Mylan has received an approvable letter from the U.S. Food and Drug Administration (FDA) in response to its New Drug Application (NDA) for nebivolol (proposed brand name Bystolic), a novel beta blocker under review for the treatment of hypertension.
In many pharmaceutical company and university laboratories, scientists are looking closely at kinase complexes because the enzymes play key roles in essential cell functions. By taking unusual steps to examine a kinase complex, researchers at Brown University and the National Institutes of Health have found a sought-after prize: an unprecedentedly detailed description of its structure complete with a rare location on its structure that could be a target for new therapeutic drugs.
› Verified 8 days ago
| Provider Name | Grace Ochs |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1558079897 PECOS PAC ID: 8729458955 Enrollment ID: I20230105000833 |
News Archive
Mindray Medical International Limited, a leading developer, manufacturer and marketer of medical devices worldwide, announced today the completion of its acquisition of Wuhan Dragonbio Surgical Implant's orthopedics business pursuant to the terms of the definitive agreement entered into on June 6, 2012.
Dendreon Corporation today announced that the U.S. Food and Drug Administration (FDA) provided written acknowledgement that the Company's amended Biologics License Application (BLA) for PROVENGE® (sipuleucel-T) is a complete response. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) date of May 1, 2010, by which time it will respond to Dendreon's amended BLA. Dendreon is seeking licensure for PROVENGE for men with metastatic castrate-resistant prostate cancer (CRPC).
Researchers have just established a structural basis for two spike glycoprotein epitopes of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that are restricted to human leukocyte antigen (HLA) A2 molecules. More specifically, they are involved in the presentation of antigenic peptides to specific T lymphocytes and recognized by public and private T cell receptors. The research is currently available on the bioRxiv* preprint server.
Forest Laboratories, Inc. and Mylan Inc. announced that Mylan has received an approvable letter from the U.S. Food and Drug Administration (FDA) in response to its New Drug Application (NDA) for nebivolol (proposed brand name Bystolic), a novel beta blocker under review for the treatment of hypertension.
In many pharmaceutical company and university laboratories, scientists are looking closely at kinase complexes because the enzymes play key roles in essential cell functions. By taking unusual steps to examine a kinase complex, researchers at Brown University and the National Institutes of Health have found a sought-after prize: an unprecedentedly detailed description of its structure complete with a rare location on its structure that could be a target for new therapeutic drugs.
› Verified 8 days ago
News Archive
Mindray Medical International Limited, a leading developer, manufacturer and marketer of medical devices worldwide, announced today the completion of its acquisition of Wuhan Dragonbio Surgical Implant's orthopedics business pursuant to the terms of the definitive agreement entered into on June 6, 2012.
Dendreon Corporation today announced that the U.S. Food and Drug Administration (FDA) provided written acknowledgement that the Company's amended Biologics License Application (BLA) for PROVENGE® (sipuleucel-T) is a complete response. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) date of May 1, 2010, by which time it will respond to Dendreon's amended BLA. Dendreon is seeking licensure for PROVENGE for men with metastatic castrate-resistant prostate cancer (CRPC).
Researchers have just established a structural basis for two spike glycoprotein epitopes of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that are restricted to human leukocyte antigen (HLA) A2 molecules. More specifically, they are involved in the presentation of antigenic peptides to specific T lymphocytes and recognized by public and private T cell receptors. The research is currently available on the bioRxiv* preprint server.
Forest Laboratories, Inc. and Mylan Inc. announced that Mylan has received an approvable letter from the U.S. Food and Drug Administration (FDA) in response to its New Drug Application (NDA) for nebivolol (proposed brand name Bystolic), a novel beta blocker under review for the treatment of hypertension.
In many pharmaceutical company and university laboratories, scientists are looking closely at kinase complexes because the enzymes play key roles in essential cell functions. By taking unusual steps to examine a kinase complex, researchers at Brown University and the National Institutes of Health have found a sought-after prize: an unprecedentedly detailed description of its structure complete with a rare location on its structure that could be a target for new therapeutic drugs.
› Verified 8 days ago
Nightingale Healthcare Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1036 S Range Line Rd, Carmel, IN 46032 Phone: 317-334-7777 Fax: 317-569-1403 | |
Hazel Dell Pediatraics, Llc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 13250 Hazel Dell Pkwy, Suite 103, Carmel, IN 46033 Phone: 317-843-9475 Fax: 317-843-9476 | |
St. Vincent Medical Group, Inc. Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 13450 N Meridian St Ste 363, Carmel, IN 46032 Phone: 317-582-8315 | |
Sports & Regenerative Medicine Pc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 12188b N Meridian St, Carmel, IN 46032 Phone: 317-660-2173 Fax: 317-660-2393 | |
Internal Medicine Of Carmel Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 11911 N Meridian St, Suite 110, Carmel, IN 46032 Phone: 317-621-1151 Fax: 317-621-1179 | |
Carmel Family Care, P.c. Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 12289 Hancock St, Suite 35, Carmel, IN 46032 Phone: 317-574-9090 Fax: 317-574-1801 | |
Ourhealth Physicians Group, Llc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 9998 N Michigan Rd, Carmel, IN 46032 Phone: 866-434-3255 |